
Hemostemix
hemostemix.com
Hemostemix is an
autologous stem cell therapy company, founded in 2003. A winner of the World
Economic Forum Technology Pioneer Award, the Company has developed, patented,
and is scaling a patient’s blood-based stem cell therapeutics platform that
includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte
cell precursors. The proprietary platform technology is backed by more than 10
years of clinical data demonstrating the ability of autologous stem cells to
regenerate diseased and damaged tissue. This platform has the potential to
generate therapies for a broad range of ischemic diseases including critical
limb ischemia, and ischemic heart disease. Under compassionate use exemption,
their lead candidate, ACP-01 has been used to treat Critical Limb Ischemia in
16 patients, with no deaths and the limbs saved on 12 of those patients.